Where We Work

The Asia and Near East (ANE) region is home to some of the world’s most populous countries. Economic instability and political tumult, combined with frequent natural disasters, contributes to increasing morbidity and mortality in poor and vulnerable subpopulations. HIV/AIDS, tuberculosis (TB), malaria, and childhood diseases cause significant death and illness in the region. RPM Plus works in South-East Asia, which bears the burden of disease in the region.  


Why We Work In ANE

Essential medicines shown to be effective in preventing and curing disease, preserving a high quality of life, and preventing mother-to-child transmission (PMTCT) are often inaccessible to poor and remote populations. High medicines costs and nutritional deficiencies both create barriers to treatment in under served populations. Affordable but counterfeit and substandard medicines, prevalent in the South-East Asian market, have an indistinguishable appearance from medicines of assured quality. Exposure to sub-therapeutic doses of antimalarial medicines has increased malaria-related morbidity, mortality, and antimicrobial resistance (AMR). Even with adequate stocks of quality medicines, problems with storage and distribution often prevent them from reaching the intended populations.

What We Do

Since 2000, RPM Plus has been providing pharmaceutical management support  for child survival, AMR, and HIV/AIDS; assistance in conducting operations research and documenting the use of incentives and enablers in finding and treating cases of TB, and supporting development of regional capacity in pharmaceutical management. A mainstay of the RPM Plus strategy has been to strengthen pharmaceutical management processes at the country level, to identify and seek solutions to pharmaceutical management issues, and to work together with partners to leverage collaborative efforts in each of the following key program areas and countries—